PALO ALTO, Calif. , Aug. 22, 2024 /PRNewswire/ -- I Peace, a pioneering CDMO in induced pluripotent stem (iPS) cells, and iCamuno Biotherapeutics, a biotech company developing iPS cell-based therapies, today announced a significant milestone with the dosing of the first patient in a clinical trial using iPS cell-derived natural killer (iNK) cells for ovarian cancer immunotherapy.
iCamuno will lead the trial, which will test the safety and efficacy of NK cells made from I Peace's cGMP-compliant iPS cells using iCamuno's NK cell differentiation technology. Natural killer (NK) cells are a critical component of the anti-cancer immune system, with natural abilities to recognize and destroy tumor cells. This trial leverages iCamuno's abilities to create cGMP-grade iPS cell-derived NK cells with improved consistency and effector function.
The initial phase will focus on ovarian cancer, with potential expansion to a broader range of diseases. "We are thrilled to reach this moment," said Koji Tanabe , CEO and founder at I Peace. "Dosing the first patient in this trial using our iPS cell line is a significant milestone in our goal to develop innovative immunotherapies for cancer.
" "This is an important milestone for iCamuno," said Ethan Liu , Chairman and co-founder of iCamuno. "Given their safety and efficacy in preclinical testing, we are hopeful that our iNK cells will be a valuable weapon in the battle against ovarian cancer." I Peace, inc.
I Peace is a biotechnology company harnes.